var data={"title":"Rasburicase: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Rasburicase: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6899?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=rasburicase-drug-information\" class=\"drug drug_general\">see &quot;Rasburicase: Drug information&quot;</a> and <a href=\"topic.htm?path=rasburicase-patient-drug-information\" class=\"drug drug_patient\">see &quot;Rasburicase: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709399\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hypersensitivity reactions:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Rasburicase may cause serious and fatal hypersensitivity reactions, including anaphylaxis. Immediately and permanently discontinue rasburicase in patients who experience a serious hypersensitivity reaction.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hemolysis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Do not administer rasburicase to patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Immediately and permanently discontinue rasburicase in patients developing hemolysis. Screen patients at higher risk for G6PD deficiency (eg, patients of African or Mediterranean ancestry) prior to starting rasburicase.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Methemoglobinemia:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Rasburicase can result in methemoglobinemia in some patients. Immediately and permanently discontinue rasburicase in patients developing methemoglobinemia.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Interference with uric acid measurements:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Rasburicase enzymatically degrades uric acid in blood samples left at room temperature. Collect blood samples in prechilled tubes containing heparin and immediately immerse and maintain sample in an ice water bath. Assay plasma samples within 4 hours of collection.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217416\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Elitek</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F854900\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Fasturtec</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061808\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Enzyme</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Uric Acid Lowering Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061801\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=rasburicase-drug-information\" class=\"drug drug_general\">see &quot;Rasburicase: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Hyperuricemia associated with malignancy:</b> Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Multiple-dosing: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling (Elitek): IV: 0.2 mg/kg/dose once daily for up to 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing (Coiffier 2008): Limited data available: IV: 0.05 to 0.2 mg/kg/dose once daily for 1 to 7 days (average: 2 to 3 days) with the duration of treatment dependent on plasma uric acid levels and clinical judgment (patients with significant tumor burden may require an increase to twice daily); the following dose levels are recommended based on risk of tumor lysis syndrome (TLS):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">High risk and baseline uric acid level &gt;7.5 mg/dL: 0.2 mg/kg/dose once daily (duration is based on plasma uric acid levels)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intermediate risk and baseline uric acid level &lt;7.5 mg/dL: 0.15 mg/kg/dose once daily (duration is based on plasma uric acid levels); may consider managing initially with a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Low risk and baseline uric acid level &lt;7.5 mg/dL: 0.1 mg/kg/dose once daily (duration is based on clinical judgment); a dose of 0.05 mg/kg was used (with good results) in one trial</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Single-dose:</i> Limited data available: IV: 0.15 mg/kg/dose; additional doses may be needed based on serum uric acid levels (Liu 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Prevention in high-risk patients with hematologic malignancies:</i> IV: 0.2 mg/kg/dose as a single dose (Jones 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Hyperuricemia associated with malignancy:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling: 0.2 mg/kg once daily for up to 5 days (use beyond 5 days or administration of more than 1 course is not recommended)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate dosing (Coiffier 2008): 0.05 to 0.2 mg/kg once daily for 1 to 7 days (average: 2 to 3 days) with the duration of treatment dependent on plasma uric acid levels and clinical judgment (patients with significant tumor burden may require an increase to twice daily); the following dose levels are recommended based on risk of tumor lysis syndrome (TLS):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">High risk: 0.2 mg/kg once daily (duration is based on plasma uric acid levels)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermediate risk: 0.15 mg/kg once daily (duration is based on plasma uric acid levels)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Low risk: 0.1 mg/kg once daily (duration is based on clinical judgment); a dose of 0.05 mg/kg was used effectively in one trial</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in thew manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217400\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Elitek: 1.5 mg (1 ea); 7.5 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217386\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061811\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Infuse over 30 minutes; do <b>not</b> administer as a bolus infusion. During administration, do not filter or mix with other medications. If not possible to administer through a separate line, IV line should be flushed with at least 15 mL NS prior to and following rasburicase infusion. The optimal timing of rasburicase administration (with respect to chemotherapy administration) is not specified in the manufacturer's labeling. In some studies, chemotherapy was administered 4 to 24 hours after the first rasburicase dose (Cortes 2010; Kikuchi 2009; Vadhan-Raj 2012); however, rasburicase generally may be administered irrespective of chemotherapy timing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217412\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">The lyophilized drug product and the diluent for reconstitution should be stored at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Protect from light. Reconstituted solution and solution diluted for infusion may be stored for up to 24 hours at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Discard unused product.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061810\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Initial management of plasma uric acid levels in patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid (FDA approved in ages &ge;1 month and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217443\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Ischemic heart disease, peripheral edema, supraventricular arrhythmia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Anxiety, headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Hyperphosphatemia, hypervolemia, hypophosphatemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal pain, constipation, diarrhea, gastrointestinal infection, mucositis, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Pulmonary hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Hyperbilirubinemia, increased serum ALT</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Hypersensitivity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Immunologic: Antibody development, development of IgG antibodies</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infection: Infection, sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Pharyngolaryngeal pain, respiratory failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Anaphylaxis, hemolysis, methemoglobinemia, seizure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217405\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">History of anaphylaxis or severe hypersensitivity to rasburicase or any component of the formulation; history of hemolytic reaction or methemoglobinemia associated with rasburicase; glucose-6-phosphatase dehydrogenase (G6PD) deficiency </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217390\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hemolysis: <b>[US Boxed Warning]: Due to the risk for hemolysis (&lt;1%), rasburicase is contraindicated in patients with G6PD deficiency. Discontinue immediately and permanently in any patient developing hemolysis. Patients at higher risk for G6PD deficiency (eg, African or Mediterranean descent) should be screened prior to therapy.</b> Severe hemolytic reactions occurred within 2 to 4 days of rasburicase initiation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity: <b>[US Boxed Warning]: Serious and fatal hypersensitivity reactions (including anaphylaxis) have been reported; immediately and permanently discontinue in patients developing a serious hypersensitivity reaction.</b> Reactions may occur at any time during treatment (including the initial dose); signs and symptoms may include bronchospasm, chest pain/tightness, dyspnea, hypotension, hypoxia, shock, or urticaria. The safety and efficacy of more than one course of administration has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Methemoglobinemia: <b>[US Boxed Warning]:  Methemoglobinemia has been reported (&lt;1%). Discontinue immediately and permanently in any patient developing methemoglobinemia.</b> Initiate appropriate treatment (eg, transfusion, methylene blue) if methemoglobinemia occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hydration: Patients at risk for tumor lysis syndrome should receive appropriate IV hydration as part of uric acid management; however, alkalinization (with sodium bicarbonate) concurrently with rasburicase is not recommended (Coiffier 2008). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Multiple courses: Rasburicase is immunogenic and can elicit an antibody response; efficacy may be reduced with subsequent courses of therapy. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Uric acid degradation: <b> [US Boxed Warning]: Enzymatic degradation of uric acid in blood samples will occur if left at room temperature, which may interfere with serum uric acid measurements; specific guidelines for the collection of plasma uric acid samples must be followed, including collection in prechilled tubes with heparin anticoagulant, immediate ice water bath immersion and assay within 4 hours (sample should remain on ice until analyzed).</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25881942\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Data suggest that children &lt;2 years of age may experience a higher frequency of adverse effects than adults, particularly vomiting (75% vs 55%), diarrhea (63% vs 20%), fever (50% vs 38%), and rash (38% vs 10%). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299985\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6222722\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12760&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217396\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217407\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects were observed in animal reproduction studies. Use during pregnancy only if the benefit to the mother outweighs the potential risk to the fetus. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061807\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Plasma uric acid levels (4 hours after rasburicase administration, then every 6 to 8 hours until TLS resolution), electrolytes, hydration status, CBC, G6PD deficiency screening (in patients at high risk for deficiency); monitor for hypersensitivity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217389\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Rasburicase is a recombinant urate-oxidase enzyme, which converts uric acid to allantoin (an inactive and soluble metabolite of uric acid); it does not inhibit the formation of uric acid.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217404\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset: Uric acid levels decrease within 4 hours of initial administration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Pediatric patients: 110 to 127 mL/kg; Adults: 76 to 138 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~16 to 23 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323780\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Elitek Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5 mg (1): $964.43</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5 mg (1): $4,822.26</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038797\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Fasturtec (AE, AT, AU, BE, BG, BR, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HN, HR, HU, IE, IN, IS, IT, KR, LB, LT, LU, MT, NL, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TR, TW, VE);</li>\n      <li>Rasuritek (JP)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Coiffier B, Altman A, Pui CH, et al, &quot;Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review,&quot; <i>J Clin Oncol</i>, 2008, 26(16):2767-78.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rasburicase-pediatric-drug-information/abstract-text/18509186/pubmed\" target=\"_blank\" id=\"18509186\">18509186</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coiffier B, Mounier N, Bologna S, et al, &quot;Efficacy and Safety of Rasburicase (Recombinant Urate Oxidase) for the Prevention and Treatment of Hyperuricemia During Induction Chemotherapy of Aggressive Non-Hodgkin's Lymphoma: Results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) Study,&quot; <i>J Clin Oncol</i>, 2003, 21(23):4402-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rasburicase-pediatric-drug-information/abstract-text/14581437/pubmed\" target=\"_blank\" id=\"14581437\">14581437</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cortes J, Moore JO, Maziarz RT, et al, &ldquo;Control of Plasma Uric Acid in Adults at Risk for Tumor Lysis Syndrome: Efficacy and Safety of Rasburicase Alone and Rasburicase Followed by Allopurinol Compared With Allopurinol Alone &ndash; Results of a Multicenter Phase III Study,&rdquo; <i>J Clin Oncol</i>, 2010, 28(27):4207-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rasburicase-pediatric-drug-information/abstract-text/20713865/pubmed\" target=\"_blank\" id=\"20713865\">20713865</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Elitek (rasburicase) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; July 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldman SC, Holcenberg JS, Finklestein JZ, et al, &ldquo;A Randomized Comparison Between Rasburicase and Allopurinol in Children With Lymphoma or Leukemia at High Risk for Tumor Lysis,&rdquo; <i>Blood</i>, 2001, 97(10):2998-3003.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rasburicase-pediatric-drug-information/abstract-text/11342423/pubmed\" target=\"_blank\" id=\"11342423\">11342423</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jeha S, Kantarjian H, Irwin D, et al, &quot;Efficacy and Safety of Rasburicase, a Recombinant Urate Oxidase (Elitek), in the Management of Malignancy-Associated Hyperuricemia in Pediatric and Adult Patients: Final Results of a Multicenter Compassionate Use Trial,&quot; <i>Leukemia</i>, 2005, 19(1):34-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rasburicase-pediatric-drug-information/abstract-text/15510203/pubmed\" target=\"_blank\" id=\"15510203\">15510203</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jones GL, Will A, Jackson GH, et al. Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. <i>Br J Haematol</i>. 2015;169(5):661-671.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rasburicase-pediatric-drug-information/abstract-text/25876990/pubmed\" target=\"_blank\" id=\"25876990\">25876990</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kikuchi A, Kigasawa H, Tsurusawa M, et al, &ldquo;A Study of Rasburicase for the Management of Hyperuricemia in Pediatric Patients With Newly Diagnosed Hematologic Malignancies at High Risk for Tumor Lysis Syndrome,&rdquo; <i>Int J Hematol</i>, 2009, 90(4):492-500.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rasburicase-pediatric-drug-information/abstract-text/19701676/pubmed\" target=\"_blank\" id=\"19701676\">19701676</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liu CY, Sims-McCallum RP, and Schiffer CA, &quot;A Single Dose of Rasburicase Is Sufficient for the Treatment of Hyperuricemia in Patients Receiving Chemotherapy,&quot; <i>Leuk Res</i>, 2005, 29(4):463-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rasburicase-pediatric-drug-information/abstract-text/15725482/pubmed\" target=\"_blank\" id=\"15725482\">15725482</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pui CH, Mahmoud HH, Wiley JM, et al, &ldquo;Recombinant Urate Oxidase for the Prophylaxis or Treatment of Hyperuricemia in Patients With Leukemia or Lymphoma,&rdquo; <i>J Clin Oncol</i>, 2001, 19(3):697-704.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rasburicase-pediatric-drug-information/abstract-text/11157020 /pubmed\" target=\"_blank\" id=\"11157020 \">11157020 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smetzer J, Cohen M, eds. Elitek diluent can be filtered. ISMP Medication Safety Alert! Acute Care Edition. 2017;22(10):3-4. Available at http://www.ismp.org/newsletters/acutecare/issue.aspx?id=1150. Accessed June 7, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vadhan-Raj S, Fayad LE, Fanale MA, et al, &ldquo;A Randomized Trial of a Single-Dose Rasburicase Versus Five-Daily Doses in Patients at Risk for Tumor Lysis Syndrome,&rdquo; <i>Ann Oncol</i>, 2012, 23(6):1640-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rasburicase-pediatric-drug-information/abstract-text/22015451/pubmed\" target=\"_blank\" id=\"22015451\">22015451</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12760 Version 75.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709399\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F217416\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F854900\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1061808\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1061801\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F217400\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F217386\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1061811\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F217412\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1061810\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F217443\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F217405\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F217390\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25881942\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299985\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6222722\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F217396\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F217407\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1061807\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F217389\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F217404\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323780\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038797\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12760|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=rasburicase-drug-information\" class=\"drug drug_general\">Rasburicase: Drug information</a></li><li><a href=\"topic.htm?path=rasburicase-patient-drug-information\" class=\"drug drug_patient\">Rasburicase: Patient drug information</a></li></ul></div></div>","javascript":null}